Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $526.3 million.

  • Entrada Therapeutics' Liabilities and Shareholders Equity fell 25.55% to $412.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 11.44%. This contributed to the annual value of $526.3 million for FY2024, which is 12.18% up from last year.
  • According to the latest figures from FY2024, Entrada Therapeutics' Liabilities and Shareholders Equity is $526.3 million, which was up 12.18% from $469.2 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Liabilities and Shareholders Equity ranged from a high of $526.3 million in FY2024 and a low of $252.1 million during FY2022.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $469.2 million (2023), whereas its average is $415.9 million.
  • Data for Entrada Therapeutics' Liabilities and Shareholders Equity shows a peak YoY soared of 86.15% (in 2023) over the last 5 years.
  • Entrada Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $252.1 million in 2022, then skyrocketed by 86.15% to $469.2 million in 2023, then increased by 12.18% to $526.3 million in 2024.